Search
Tegaserod
go.drugbank.com/drugs/DB01079ApprovedWithdrawnin female patients less than 65 years of age and whom are considered to be at a lower risk of a cardiovascular event than the broader population. … [L5918,F4229] Since then, closer evaluations of the original data suggesting such cardiovascular risk have resulted in the limited reintroduction or 're-approval' of tegaserod for treatment of IBS-C specifically
Categories: Drugs for ConstipationRituximab
go.drugbank.com/drugs/DB00073ApprovedInvestigationalFDA in 1997 as a single agent to treat patients with B-cell Non-Hodgkin's Lymphoma (NHL) [L4811], however, has now been approved for a variety of conditions [FDA label]. … Rituximab is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes.
Categories: Biologics for Rheumatoid Arthritis TreatmentProducts: MABTHERA ROCHE SOLUCION PARA INFUSION 10 MG/ML, Mabthera Concentrate for Solution for Infusion 100mg/10mlUbrogepant
go.drugbank.com/drugs/DB15328ApprovedInvestigational[L10959] Several oral small molecule CGRP receptor antagonists, belonging to a class of medications referred to as "gepants", have been investigated for migraines, but only ubrogepant and [rimegepant] … Ubrogepant is indicated for the acute treatment of migraine headaches with or without aura in adults.
Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substratesEnfuvirtide
go.drugbank.com/drugs/DB00109ApprovedInvestigationalEnfuvirtide is a 36 amino acid biomimetic peptide that is structurally similar to the HIV proteins that are responsible for the fusion of the virus to cell membranes and subsequent intracellular uptake
Categories: Antivirals for Systemic Use, Antiinfectives for Systemic UseVenlafaxine
go.drugbank.com/drugs/DB00285ApprovedInvestigationalIt was also considered a second-line treatment for obsessive-compulsive disorder (OCD). … [A252065] Venlafaxine has been used as a first-line treatment for MDD, GAD, social anxiety disorder, and panic disorder in Canada for many years.
Categories: Antidepressive Agents Indicated for DepressionProducts: VENLAFAXIN AL 75MG REK, VENLAFAXIN 1A 75MG REKVecuronium
go.drugbank.com/drugs/DB01339ApprovedInvestigationalA non-depolarizing neuromuscular blocking agent with shorter duration of action than pancuronium. … Its lack of significant cardiovascular effects and lack of dependence on good kidney function for elimination as well as its short duration of action and easy reversibility provide advantages over, or
Products: Vecuronium Bromide for Injection, VECURONIUM BROMIDE FOR INJECTIONSpironolactone
go.drugbank.com/drugs/DB00421ApprovedInvestigationalSpironolactone is a potassium-sparing diuretic. It binds to mineralocorticoid receptors and functions as aldosterone antagonists. … [A11837] Spironolactone was originally developed purely for this ability before other pharmacodynamic properties of the drug were discovered.
Categories: Antihypertensive Agents Indicated for HypertensionProducts: ALDACTONE A, SPIRONOLACTON AL 50Sulconazole
go.drugbank.com/drugs/DB06820ApprovedSulconazole, brand name Exelderm, is a broad-spectrum anti-fungal agent available as a topical cream and solution. … Sulconazole nitrate, the active ingredient, is an imidazole derivative that inhibits the growth of common pathogenic dermatophytes, making it an effective treatment for tinea cruris and tinea corporis
Categories: Antifungals for Topical Use, Antifungals for Dermatological UseLinvoseltamab
go.drugbank.com/drugs/DB17447ApprovedInvestigationalFDA in July 2025 for patients who have undergone four or more prior lines. Continued approval in the U.S. is contingent upon verification of clinical benefit in a confirmatory trial. [L53363] … This mechanism results in the targeted release of cytokines such as IL-2, IL-6, and IFN-gamma, promoting the selective lysis of BCMA-expressing cells and offering a novel immunotherapeutic approach for
Fidanacogene elaparvovec
go.drugbank.com/drugs/DB16783ApprovedInvestigationalCurrent available treatments include substitution therapy involving the intravenous administration of standard factor IX once a week for bleeding or as prophylaxis and 2–3 times a week for severe hemophilia … Fidanacogene elaparvovec is a liver-specific adeno-associated virus (AAV) vector containing a codon-optimized human coagulation FIX gene that was investigated as a potential treatment for hemophilia B.